NASDAQ:GNMX - Aevi Genomic Medicine Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.20 0.00 (0.00 %) (As of 05/26/2019 01:53 PM ET)Previous Close$0.2030Today's Range$0.1860 - $0.205052-Week Range$0.17 - $1.72Volume312,827 shsAverage Volume2.36 million shsMarket Capitalization$13.15 millionP/E RatioN/ADividend YieldN/ABeta0.59 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania. Receive GNMX News and Ratings via Email Sign-up to receive the latest news and ratings for GNMX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNMX Previous SymbolNASDAQ:MDGN CUSIPN/A CIK1138776 Webhttp://www.aevigenomics.com/ Phone610-254-4201Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book3.38Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-30,770,000.00 Net MarginsN/A Return on Equity-264.57% Return on Assets-178.51%Miscellaneous Employees14 Outstanding Shares64,767,000Market Cap$13.15 million Next Earnings Date5/28/2019 (Estimated) OptionableOptionable Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions What is Aevi Genomic Medicine's stock symbol? Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX." How were Aevi Genomic Medicine's earnings last quarter? Aevi Genomic Medicine Inc (NASDAQ:GNMX) posted its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. View Aevi Genomic Medicine's Earnings History. When is Aevi Genomic Medicine's next earnings date? Aevi Genomic Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, May 28th 2019. View Earnings Estimates for Aevi Genomic Medicine. What is the consensus analysts' recommendation for Aevi Genomic Medicine? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aevi Genomic Medicine in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aevi Genomic Medicine. Has Aevi Genomic Medicine been receiving favorable news coverage? News articles about GNMX stock have trended negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Aevi Genomic Medicine earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the next few days. Who are some of Aevi Genomic Medicine's key competitors? Some companies that are related to Aevi Genomic Medicine include Cidara Therapeutics (CDTX), Curis (CRIS), Pharmacyte Biotech (PMCB), BioCardia (BCDA), BIONDVAX PHARMA/S (BVXV), Entera Bio (ENTX), Outlook Therapeutics (OTLK), Vical (VICL), Microbot Medical (MBOT), TRACON Pharmaceuticals (TCON), aTyr Pharma (LIFE), CytRx (CYTR), Titan Pharmaceuticals (TTNP), Windtree Therapeutics (WINT) and TrovaGene (TROV). What other stocks do shareholders of Aevi Genomic Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Immunomedics (IMMU), Novavax (NVAX), Protalix Biotherapeutics (PLX), ACADIA Pharmaceuticals (ACAD), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Amicus Therapeutics (FOLD) and TransEnterix (TRXC). Who are Aevi Genomic Medicine's key executives? Aevi Genomic Medicine's management team includes the folowing people: Mr. Michael F. Cola, CEO, Pres & Director (Age 59)Mr. Brian D. Piper, CFO & Corp. Sec. (Age 47)Dr. Garry A. Neil, Chief Scientific Officer (Age 65) Who are Aevi Genomic Medicine's major shareholders? Aevi Genomic Medicine's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.69%), Virtu Financial LLC (0.43%) and Acadian Asset Management LLC (0.41%). Company insiders that own Aevi Genomic Medicine stock include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Institutional Ownership Trends for Aevi Genomic Medicine. Which institutional investors are buying Aevi Genomic Medicine stock? GNMX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC and Virtu Financial LLC. Company insiders that have bought Aevi Genomic Medicine stock in the last two years include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Insider Buying and Selling for Aevi Genomic Medicine. How do I buy shares of Aevi Genomic Medicine? Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aevi Genomic Medicine's stock price today? One share of GNMX stock can currently be purchased for approximately $0.2030. How big of a company is Aevi Genomic Medicine? Aevi Genomic Medicine has a market capitalization of $13.15 million. Aevi Genomic Medicine employs 14 workers across the globe. What is Aevi Genomic Medicine's official website? The official website for Aevi Genomic Medicine is http://www.aevigenomics.com/. How can I contact Aevi Genomic Medicine? Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected] MarketBeat Community Rating for Aevi Genomic Medicine (NASDAQ GNMX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 161 (Vote Outperform)Underperform Votes: 168 (Vote Underperform)Total Votes: 329MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/26/2019 by MarketBeat.com StaffFeatured Article: What does a dividend yield signify to investors? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.